Vinod Mohan, MD
Infectious Disease · Bangor, MENPI 1326351594
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Johnson & Johnson at 32.4% of the total. Reporting peaked in 2022 at $1,174 and has fallen 96.6% since, to $40 in 2024. Among infectious disease clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$515
- AbbVie$236
- Novo Nordisk$125
- Amgen$110
- Lilly USA, LLC$80
- Merck$80
- plus $442 from 12 others
What the payments were for
- Food & beverage$1,589100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 16 | $515 |
| AbbVie | 9 | $236 |
| Novo Nordisk | 6 | $125 |
| Amgen | 5 | $110 |
| Lilly USA, LLC | 4 | $80 |
| Merck | 4 | $80 |
| Pfizer | 3 | $72 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $63 |
| Novartis | 2 | $48 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| AstraZeneca | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $23 |
| GSK | 1 | $21 |
| Bayer | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,589 in reported general payments places this provider in the 90th percentile of 29 infectious disease providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 39 | $157,947 |
| TivicayDolutegravir Sodium | 25 | $59,947 |
| DescovyEmtricitabine/Tenofov Alafenam | 25 | $58,483 |
| JulucaDolutegravir/Rilpivirine | 13 | $52,897 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $47,127 |
| VemlidyTenofovir Alafenamide | 12 | $16,839 |
| Amikacin Sulfate | 21 | $2,356 |
| Rifabutin | 12 | $1,708 |
| CeftriaxoneCeftriaxone Sodium | 12 | $707 |
| Ethambutol Hcl | 11 | $558 |
| Azithromycin | 11 | $9 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Bangor
- Rebekah GassBangor$528
- Eleanor StedmanBangor$113
- Mohamedazhar GangatBangor$109
- Mark AbelBangor$20
- Ahmad HamdanBangor$0
- Michael CoyneBangor$0
- Christina YenPortland$10K
- Daniel DiekemaSouth Portland$2K
- Patricia StogsdillSouth Portland$740
- Matthew CarrollBath$501
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.